Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 2 of 14
Sep 23, 2026The Swiss drugmaker said the agreement complements its radioligand portfolio, even though details of the licensed program were not disclosed. The timing is notable: Novartis is reinforcing a core oncology franchise just after abandoning one midstage asset and as a stronger rival platform begins to form around Telix and ITM.
Sep 21, 2026TRex would use IPO proceeds to move a Treg-focused autoimmune pipeline forward, while Retension is centered on taking RTN-001 through a phase 2b study and into phase 3 in uncontrolled hypertension. The paired filings suggest the current IPO window is open to very different biotech profiles, as long as the use of capital is tightly linked to near-term development steps.
Sep 20, 2026The Boston-based company serves employers, payers and providers with virtual care for digestive issues including abdominal pain, bloating, constipation and weight gain. The new round, led by Neon, brings Ayble Health’s total funding to more than $27 million and signals investor interest in specialty virtual care models that are trying to connect overlapping chronic conditions rather than treat them separately.
Sep 18, 2026Electra sold 23.3 million shares at $15 each, with underwriters holding a 30-day option to buy up to 3.5 million more shares. The company plans to direct most of the proceeds toward ipsoprubart in secondary hemophagocytic lymphohistiocytosis and related malignancy studies, while also advancing ELA822.
Sep 11, 2026The raise adds to a month that has already featured multiple sizable life sciences financings. For investors and biotech executives, the signal is that specialist capital is still being assembled for public-company opportunities even as the sector remains selective about where that money goes.
Sep 10, 2026The New York-based firm said LumaBio Fund I is designed to support companies from discovery through commercialization. Its existing portfolio includes Character Biosciences, Coultreon Biopharma and Altos Labs, and one co-founded company, Vaccine Company, was acquired by Eli Lilly earlier this year for up to $1.55 billion.
Sep 10, 2026The financing backs both late-development execution and infrastructure, with Encoded pairing a registration-directed program in Dravet syndrome with a commercial manufacturing build-out. That combination signals that investors are still willing to fund genetic medicines when companies can point to clinical traction and a clearer path toward control of supply.
Sep 9, 2026Solstice was founded in February and quickly licensed porustobart from Harbour BioMed for development and commercialization outside of China under a deal that included a $105 million upfront package. Its financing now funds a phase 2 trial in a patient population the company says has yet to benefit from immunotherapy, with enrollment due to begin this year or in the fourth quarter depending on the source and data expected in the second half of 2027.
Sep 9, 2026BioSpace reports that crossover rounds began picking up around the fourth quarter of 2025, before the current IPO boom became obvious. The pattern suggests public investors did not abandon biotech during the downturn; instead, they accepted longer timelines and are now helping restock the listing pipeline as the market reopens.
Sep 9, 2026Moonwalk is positioning MW101 as a long-lasting RNAi-based obesity candidate after preclinical mouse data showed weight loss and fat reduction while maintaining muscle mass without reducing food intake. The round adds to a $57 million seed launch in early 2024 and highlights continued investor interest in differentiated metabolic programs despite a market dominated by GLP-1 drugs.
Sep 8, 2026The financing gives the Seattle Children’s Hospital spinout enough capital to continue its lead effort in diffuse intrinsic pontine glioma, or DIPG, where BrainChild is running an open-label, single-arm phase 2 study of BCB-276. Across the available reporting, the raise is described as $116 million by Fierce Biotech and $119 million by BioSpace, a discrepancy the company’s sourced coverage does not resolve.
Sep 7, 2026ADARx Pharmaceuticals is seeking fresh public-market capital despite entering 2026 with $427.3 million in cash, using the offering to support a wide clinical agenda across complement, hereditary angioedema and thrombosis-related programs. The move adds to this year's biotech IPO wave while showing that investors are again being asked to fund platform breadth, not just a single lead asset.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.